Frequency of vaccine-related reactogenicity events and other adverse events Throughout study [clinicaltrials_resource:bcee6b8f3557f6b12aa39bce260a9f2c]
Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Frequency of vaccine-related reactogenicity events and other adverse events Throughout study [clinicaltrials_resource:bcee6b8f3557f6b12aa39bce260a9f2c]
Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
Bio2RDF identifier
bcee6b8f3557f6b12aa39bce260a9f2c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:bcee6b8f3557f6b12aa39bce260a9f2c
measure [clinicaltrials_vocabulary:measure]
Frequency of vaccine-related reactogenicity events and other adverse events
time frame [clinicaltrials_vocabulary:time-frame]
Throughout study
description
Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
identifier
clinicaltrials_resource:bcee6b8f3557f6b12aa39bce260a9f2c
title
Frequency of vaccine-related r ...... dverse events Throughout study
@en
type
label
Frequency of vaccine-related r ...... e6b8f3557f6b12aa39bce260a9f2c]
@en